Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Mind Medicine (MindMed) Inc
Other Items
Mind Medicine (MindMed) Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other Items
-$186.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other Items
-$188m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
36%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Other Items
CA$28.3m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
43%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Other Items
-CA$13m
|
CAGR 3-Years
64%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Other Items
-$50.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other Items
-CA$19.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
Mind Medicine (MindMed) Inc
Glance View
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
See Also
What is Mind Medicine (MindMed) Inc's Other Items?
Other Items
-186.6m
USD
Based on the financial report for Sep 30, 2025, Mind Medicine (MindMed) Inc's Other Items amounts to -186.6m USD.
